Aortyx

Aortyx

Aortyx has developed a biomimetic bioresorbable adhesive patch to treat aortic dissections. It helps to stop false lumen blood flow, promotes natural repair and bio integration. Learn more

Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR201920202021
Revenues<1m<1m<1m
% growth-(93 %)1830 %
EBITDA(<1m)(<1m)(<1m)
% EBITDA margin(25 %)(7 %)(535 %)
Profit(<1m)(<1m)(<1m)
% profit margin(49 %)(877 %)(436 %)

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound

N/A

Spinout

€70.0k

Grant

N/A

Spinout

€50.0k

Grant

€50.0k

Grant
*

€650k

Valuation: €1.5m

Seed

€250k

Grant

€175k

Grant

€550k

Debt
*

€2.4m

Seed
*

€2.5m

Grant

N/A

Early VC
Total FundingCAD9.2m

Recent News about Aortyx

Edit
More about Aortyx
Edit

Developer of endovascular devices intended to treat vascular diseases. The company's devices focus on tissue regeneration by mimicking the aorta biomechanical environment and provide a suitable milieu for cell migration and proliferation in a bioresorbable platform that minimizes differences with the natural dynamics of the aorta, enabling professionals to treat vascular diseases in an efficient manner.

Keywords: Healthcare Devices, Services, Supplies, Aortic Disease Treatment, Biomechanical Environment, Cell Migration, Cell Proliferation, Endovascular Device, Vascular Disease.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.